Precision prevention and cancer interception: The new challenges of liquid biopsy

Fecha de publicación: 01/01/2020

Autores organización

Andres Felipe Cardona Mendoza

Autor

Autores

Serrano M.J.
Garrido-Navas M.C.
Mochon J.J.D.
Cristofanilli M.
Gil-Bazo I.
Pauwels P.
Malapelle U.
Russo A.
Lorente J.A.
Ruiz-Rodriguez A.J.
Paz-Ares L.G.
Vilar E.
Raez L.E.
Rolfo C.

Grupos de investigación

Grupo de Inmunología celular y molecular Universidad El Bosque (InmuBo)

Investigador

Maria Consuelo Romero Sanchez

Resumen

Despite major therapeutic progress, most advanced solid tumors are still incurable. Cancer interception is the active way to combat cancer onset, and development of this approach within high-risk populations seems a logical first step. Until now, strategies for the identification of high-risk subjects have been based on low-sensitivity and low-specificity assays. However, new liquid biopsy assays, “the Rosetta Stone of the new biomedicine era,” with the ability to identify circulating biomarkers with unprecedented sensitivity, promise to revolutionize cancer management. This review focuses on novel liquid biopsy approaches and the applications to cancer interception. Cancer interception involves the identification of biomarkers associated with developing cancer, and includes genetic and epigenetic alterations, as well as circulating tumor cells and circulating epithelial cells in individuals at risk, and the implementation of therapeutic strategies to prevent the beginning of cancer and to stop its development. Large prospective studies are needed to confirm the potential role of liquid biopsy for early detection of precancer lesions and tumors. ©2020 American Association for Cancer Research.

Datos de la publicación

ISSN/ISSNe:: 2159-8274, 2159-8290
Tipo:: Article
Páginas:: 1635-1644
DOI:: 10.1158/2159-8290.CD-20-0466
PubMed:: 33037026
Enlace a otro recurso:: www.scopus.com

Documentos

No hay documentos

Métricas

Filiaciones

Serrano M.J.:: GENYO Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain

Bio-Health Research Institute (Instituto de Investigación Biosanitaria ibs. GRANADA), Hospital Universitario Virgen de las Nieves Granada, Department of Medical Oncology, University of Granada, Granada, Spain

Department of Pathological Anatomy, Faculty of Medicine, Campus de Ciencias de la Salud, University of Granada, Granada, Spain
Garrido-Navas M.C.:: GENYO Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain
Mochon J.J.D.:: GENYO Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain

DestiNA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Armilla, Granada, Spain

Department of Medicinal and Organic Chemistry, School of Pharmacy, University of Granada, Granada, Spain
Cristofanilli M.:: Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Com-prehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
Gil-Bazo I.:: Department of Oncology, Clínica Universi-dad de Navarra, Pamplona, Spain
Pauwels P.:: Department of Pathology, University Hospital Antwerp, Belgium & Center for Oncological Research (CORE), Antwerp University, Belgium
Malapelle U.:: Department of Public Health, University of Naples “Federico II,” Naples, Italy
Russo A.:: Medical Oncology Unit, A.O. Papardo, Messina, Italy
Lorente J.A.:: GENYO Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain

Laboratory of Genetic Identification, Department of Legal Medicine, University of Granada, Granada, Spain
Ruiz-Rodriguez A.J.:: Unit of gastroen-terology and hepatology, University Hospital Clínico San Cecilio, Granada, Spain
Paz-Ares L.G.:: Division of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
Vilar E.:: Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Raez L.E.:: Memorial Cancer Institute, Memorial Health Care System, Florida International University, Miami, FL, United States
Cardona A.F.:: Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia

Foundation for Clinical and Applied Cancer Research –FICMAC, Bogotá, Colombia

Universidad. Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Rolfo C.:: Thoracic Oncology & Experimental Therapeutics Program, Greenebaum Compre-hensive Cancer Center, University of Maryland School of Medicine, Balti-more, MD, United States

Keywords

Humans; Liquid Biopsy; Neoplasms; Precision Medicine; biological marker; carcinoembryonic antigen; circulating tumor DNA; cyclin dependent kinase 6; K ras protein; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; prostate specific antigen; apoptosis; Article; body mass; breast cancer; cancer mortality; cancer prevention; cancer risk; cancer screening; chronic obstructive lung disease; colonoscopy; colorectal cancer; DNA methylation; dyspnea; endothelial progenitor cell; epigenetics; genetic marker; genetic susceptibility; health behavior; high risk population; human; hypertension; interstitial lung disease; liquid biopsy; machine learning; mammography; metastasis; non small cell lung cancer; ovary cancer; pancreas adenocarcinoma; pancreas islet cell tumor; personalized medicine; plasmacytoma; questionnaire; RNA sequence; six minute walk test; somatic mutation; squamous cell carcinoma; tumor biopsy; neoplasm; procedures